Recommended

Ph. Eur. Commission updates mAb standards
FDA approves Omisirge cell therapy for severe aplastic anaemia
Increasing the effectiveness of pharma endotoxin testing | REGISTER NOW
Pfizer $2bn GLP-1 YaoPharma deal
Lilly furthers US onshoring with new manufacturing facility
Europe makes progress in agreeing new pharma legislation
J&J biologics demonstrate potential in multiple myeloma
Moderna expands mRNA drug delivery capabilities
WEBINAR: reflections and future opportunities in pharmaceutical microbiology
CSL invests $1bn in new vaccine manufacturing facility
CHMP recommends two new cancer drugs in Dec 2025 meeting
news

Sanofi $1.6 billion acquisition to advance respiratory vaccines

1
SHARES

The new deal could support innovation of next-generation combination vaccines to protect older adults against multiple respiratory viruses.

Sanofi Vicebio

Sanofi has agreed to acquire the biotech Vicebio for an upfront payment of $1.15 billion, supporting the advancement of respiratory virus vaccines.

 

SECURE YOUR FREE SPOT

 


This webinar explores how the pharmaceutical industry can move towards sustainable autonomous operations.

Realising autonomous pharmaceutical operations | 9 February 2026 | 10am

What you’ll discover:

  • Understand the key drivers of the pharmaceutical industry and how autonomous operations are shaping its future and driving IT-OT conversion
  • Explore the value of automation in enhancing operational efficiency and driving business growth for life sciences
  • Gain expert insight on the potential benefits of implementing automation solutions.

Register now – it’s free

In addition to the initial payment, Sanofi will pay up to $450 million, subject to achieved development and regulatory milestones.

The deal intends to expand capabilities in vaccine design and development and will enable Sanofi to add a non-mRNA vaccine to its development pipeline.

Specifically, the new agreement involves a combination vaccine candidate to immunise against both respiratory syncytial virus (RSV) and a human metapneumovirus (hMPV).

Advancing vaccine design through Sanofi’s acquisition of Vicebio

This acquisition by Sanofi adds ‘Molecular Clamp’ technology, which stabilises viral proteins in their native shape, enhancing the immune system’s ability to respond to these proteins.

“This acquisition…[has] potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunisation”

This innovative approach provides a shorter development timeline for fully liquid combination vaccines stored at standard refrigeration temperatures (2–8°C). This removes the need for freezing or freeze-drying and simplifies manufacturing. There is also capability for fully liquid vaccines to be administered via prefilled syringes, making them safer and easier to use, Sanofi explained.

Vicebio’s pipeline includes VXB-241, a bivalent vaccine candidate, currently being evaluated in a Phase I study in older adults to protect against RSV and hMPV. The products in development are intended to offer broad protection and have high manufacturability, Vicebio shared on its website.  

“This acquisition furthers Sanofi’s dedication to vaccine innovation with the potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunisation,” explained Jean-François Toussaint, Global Head of Research and Development Vaccines at Sanofi.

The transaction between Sanofi and Vicebio is expected to close in the final quarter of 2025, subject to customary closing conditions.

 
Share via
Share via